Intimal Arteritis and Microvascular Inflammation Are Associated With Inferior Kidney Graft Outcome, Regardless of Donor-Specific Antibodies

Marek Novotny1,2, Petra Hruba3, Martin Kment4, Lukas Voska4, Katerina Kabrtova5, Antonij Slavcev5 and Ondrej Viklicky1,2,*

1 Department of Nephrology, Transplant Centre, Institute for Clinical and Experimental Medicine, Prague, Czechia, 2 Institute of Physiology, First Medical Faculty, Charles University, Prague, Czechia, 3 Transplant Laboratory, Transplant Centre, Institute for Clinical and Experimental Medicine, Prague, Czechia, 4 Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czechia, 5 Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czechia

Background: The prognostic role of intimal arteritis of kidney allografts in donor-specific antibody negative (DSA–) antibody-mediated rejection (AB MR) remains unclear.

Methods: Seventy-two out of 881 patients who had undergone kidney transplantation from 2014 to 2017 exhibited intimal arteritis in biopsies performed during the first 12 months. In 26 DSA negative cases, the intimal arteritis was accompanied by tubulointerstitial inflammation as part of T cell-mediated vascular rejection (TCMRV, N = 26); intimal arteritis along with microvascular inflammation occurred in 29 DSA negative (ABMRV/DSA–) and 19 DSA positive cases (ABMRV, DSA+, N = 17). In 60 (83%) patients with intimal arteritis, the surveillance biopsies after antirejection therapy were performed. Hundred and two patients with non-vascular ABMR with DSA (ABMR/DSA+, N = 55) and without DSA (ABMR/DSA–, N = 47) served as controls.

Results: Transplant glomerulopathy-free survival at 36 months was 100% in TCMRV, 85% in ABMR/DSA–, 65% in ABMRV/DSA–, 54% in ABMRV/DSA+ and 31% in ABMRV/DSA+ (log rank p < 0.001). Death-censored graft survival at 36 months was 98% in ABMR/DSA–, 96% in TCMRV, 86% in ABMRV/DSA–, 79% in ABMRV/DSA+, and 64% in ABMRV/DSA+ group (log rank p = 0.001). In surveillance biopsies, the resolution of rejection was found in 19 (90%) TCMRV, 14 (58%) ABMRV/DSA–, and only 4 (27%) ABMRV/DSA+ patients (p = 0.006). In the multivariable model, intimal arteritis as part of ABMR represented a significant risk for TG development (HR 2.1, 95% CI 1.2–3.8; p = 0.012) regardless of DSA status but not for graft failure at 36 months.

Conclusions: Intimal arteritis as part of ABMR represented a risk for early development of TG regardless of the presence or absence of DSA. Intimal arteritis in DSA positive ABMR represented the high-risk phenotype.

Keywords: antibody-mediated rejection, intimal arteritis, kidney transplantation, vascular rejection, rejection diagnostics
INTRODUCTION

Antibody-mediated rejection (ABMR) represents a major obstacle in achieving long-term graft function and survival (1). Its diagnosis is based on histology and detection of donor-specific antibodies (DSA) (2). Overlapping phenotypes and cases with incomplete manifestation represent a considerable part of diagnoses in clinical practice (3).

Intimal arteritis, i.e., v-lesion defined by Banff histological criteria, is a morphologic feature of vascular rejection. It represents a diagnostic and therapeutic challenge as it is involved in histologic criteria of both T cell-mediated rejection (TCMR) and ABMR (2). Although, previously intimal arteritis was recognized as the rejection phenotype often resistant to steroid treatment (4), more recently, the association of intimal arteritis with DSA was described (5). Lefaucheux et al. revealed a detrimental impact of intimal arteritis associated with DSA on graft prognosis exceeding other rejection phenotypes, and thus any grade of intimal arteritis has been included in the Banff classification as a histologic feature of ABMR (6).

Almost half of the patients with histological features of ABMR in DSA negative patients do not fit the current Banff classification (7). Intimal arteritis is frequently present in both TCMR and ABMR occurring early after kidney transplantation (8). Although a negative prognostic role of DSA in ABMRV has been well-documented (5), the outcome of ABMRV in DSA negative patients remains poorly understood. Therefore, in this study, we compared the outcome of intimal arteritis as part of both T cell-mediated vascular rejection (TCMRV) and antibody-mediated vascular rejection (ABMRV) with ABMR without intimal arteritis in patients with and without DSA in terms of premature graft loss and transplant glomerulopathy (TG) development.

MATERIALS AND METHODS

Study Design and Population

In this single center retrospective observational cohort study, we evaluated the outcome and clinical relevance of intimal arteritis in the early posttransplant biopsies performed within 12 months from January 2014 to December 2017. For comparison, we retrospectively reviewed medical records of 881 patients who had undergone kidney transplantation at the same time to identify those with histologic features of ABMR in early biopsies and enrolled them for further investigation. Data collection was finalized in January 2021 when all the study subjects reached a 3-year follow-up. Demographics of the study cohort are given in Table 2 and the enrollment is described in Figure 1. All patients signed the informed consent with case or surveillance biopsies and medical data assessment, and the local Ethical Board approved the study under No.: 15-265191A.

Histopathology and the Definition of Rejection Phenotype Categories

Kidney allograft biopsies were performed using a percutaneous ultrasound-guided 16G biopsy needle. Diagnoses of acute rejection were established at a median time 70 days after transplantation by for-cause biopsies in 120 (69%) of patients. Fifty-two (31%) rejections were found in protocol biopsies at the third month after transplantation.

Biopsy samples were assessed for Banff scored lesions (2) as glomerulitis (g), peritubular capillaritis (ptc), transplant glomerulopathy (cg), intimal arteritis (v), interstitial inflammation (i), tubulitis (t), mesangial matrix increase (mm), vascular intimal fibrosis (cv), arteriolar hyaline thickening (ah), interstitial fibrosis (ci), or tubular atrophy (ct). The microvascular inflammation (MVI) score was defined as the sum of glomerular (g) and peritubular capillary inflammation (ptc). Immunofluorescence detection of C4d was performed in all cases.

Patients with glomerulitis, peritubular capillaritis, intimal arteritis, and/or TG were divided into five groups (TCMRV N = 26, ABMRV/DSA– N = 29, ABMRV/DSA+ N = 17, ABMR/DSA– N = 47, ABMR/DSA+ N = 55) according to the histopathological finding and presence or absence of DSA (Table 1).

T cell-mediated vascular rejection was characterized by intimal arteritis and tubulointerstitial inflammation (TI) in the absence of glomerulitis of rejection origin, C4d, and DSA. ABMRV included features of MVI and C4d (positive or negative) in addition to v-lesion. Patients were further divided according to their DSA status as ABMRV/DSA– when DSA were negative and ABMRV/DSA+ when DSA were positive. ABMR, defined by the presence of MVI and C4d (positive or negative), were further divided according to DSA status as described above (ABMR/DSA–, ABMR/DSA+). Four phenotypes fulfilling criterion 1 (histologic evidence of acute tissue injury) and 2 (evidence of recent antibody interaction with endothelium) of Banff ABMR definition were called histologic ABMR groups.

Anti-HLA Antibody Testing

Identification of circulating donor-specific anti-HLA antibodies (DSA) was performed by Luminex bead-based assay (One Lambda Inc., Canoga Park, CA, USA). Class I A, B, and class II DR antibodies were evaluated for specificity after transplantation. Class II DP and DQ antibodies were evaluated for specificity after transplantation because donors’ HLA DP or DQ typing was not available at the time of transplantation. DSA positivity at the time of transplantation was revealed in 14 (82%) of the patients with ABMRV/DSA+ and 47 (86%) of them with ABMR/DSA+. In the rest of the patients from these phenotype categories, DSA was detected at the time of diagnostic biopsy.

Immunosuppressive Treatment

Patients received maintenance immunosuppression based on tacrolimus, mycophenolate mofetil, and corticosteroids. All patients received induction treatment. Patients at low risk (N = 73) received basiliximab whereas those at high risks, such as retransplants and patients with anti-HLA antibodies or DSA, received rabbit anti-thymocyte globulin (rATG) (N = 49). Patients with DSA positivity (<5,000
TABLE 1 | Definition of the rejection phenotype groups.

|                | g  | ptc | v  | l   | t   | C4d | DSA |
|----------------|----|-----|----|-----|-----|-----|-----|
| TCMRV          | 0  | >0* | >1 | 0–3 | 0–3 | 0   | Neg |
| ABMRV/DSA–     | 0–3| >0* | >1 | 0–3 | 0–3 | 0–3 | Neg |
| ABMRV/DSA+     | 0–3| >0* | >1 | 0–3 | 0–3 | 0–3 | Pos |
| ABMRV/DSA–     | 0–3| >0* | 0  | 0–3 | 0–3 | 0–3 | Neg |
| ABMRV/DSA+     | 0–3| >0* | 0  | 0–3 | 0–3 | 0–3 | Pos |

*In presence of tubulointerstitial inflammation ptc alone was not evaluated as ABMR criterion.

TABLE 2 | Overview of the baseline characteristics of all rejection phenotype groups.

|                              | Total | TCMRV | ABMRV/DSA– | ABMRV/DSA+ | ABMRV/DSA– | ABMRV/DSA+ | P-value |
|------------------------------|-------|-------|------------|------------|------------|------------|---------|
| N                            | 174   | 26    | 29         | 17         | 47         | 55         |         |
| Age, yr (range)              | 53 (21–81) | 54 (23–70) | 56 (23–81) | 49 (25–78) | 56 (21–71) | 48 (23–78) | 0.121   |
| Gender (female)              | 62 (36) | 8 (31) | 11 (38)    | 5 (29)     | 15 (32)    | 23 (42)    | 0.768   |
| Dialysis vintage, m (range)  | 26 (0–263) | 20 (0–263) | 25 (0–118) | 32 (0–131) | 21 (0–128) | 38 (0–139) | 0.046   |
| PRA max, % (range)           | 7 (0–100)  | 2 (0–69) | 5 (29)     | 5 (29)     | 15 (98)    | 32 (100)   | <0.001  |
| HLA mismatch, % (range)      | 3 (0–6)   | 4 (1–6)  | 3 (0–6)    | 4 (2–6)    | 3 (0–6)    | 3 (1–6)    | 0.14    |
| 1st transplantation (%)      | 123 (71) | 24 (92) | 27 (93)    | 8 (47)     | 45 (96)    | 19 (35)    | <0.001  |
| DSA at Tx, n (%)             | 61 (35) | 0     | 14 (52)    | 0          | 47 (86)    | 0          | 0.756*  |
| DSA class I, n (%)           | 23 (13) | 0     | 3 (18)     | 0          | 20 (36)    | 0          | 0.148*  |
| DSA class II, n (%)          | 28 (16) | 0     | 8 (46)     | 0          | 20 (36)    | 0          | 0.720*  |
| DSA both classes, n (%)      | 21 (12) | 0     | 6 (36)     | 0          | 15 (28)    | 0          | 0.525*  |
| FACS T at biopsy, %          | 104/19 (18) | 14/2 (14) | 28/3 (12)  | 14/3 (21)  | 18/0       | 32/10 (31) | <0.001  |
| FACS B at biopsy, %          | 104/31 (29) | 14/1 (7)  | 26/0       | 14/8 (57)  | 18/5 (5)   | 32/21 (65) | <0.001  |
| Cold ischemia, h (range)     | 14 (0.3–24) | 13 (0.3–21) | 13 (0.3–20) | 16 (0.5–23) | 14 (0.5–23) | 15 (0.6–24) | 0.26    |
| Deceased donor, n (%)        | 146 (84) | 17 (65)  | 23 (79)    | 15 (88)    | 39 (83)    | 52 (95)    | 0.018   |
| CKD diagnosis                |       |       |            |            |            |            | 0.039   |
| Diabetes                    | 23 (13) | 3 (12)  | 6 (21)     | 2 (12)     | 11 (23)    | 1 (2)      |         |
| Vascular + TIN              | 41 (24) | 10 (39) | 8 (28)     | 5 (29)     | 6 (13)     | 12 (22)    |         |
| Glomerulonephritis          | 50 (29) | 4 (15)  | 5 (17)     | 5 (29)     | 14 (30)    | 22 (40)    |         |
| Hereditary nephropathy       | 35 (20) | 6 (23)  | 5 (17)     | 1 (6)      | 8 (17)     | 15 (27)    |         |
| Other                       | 25 (14) | 3 (12)  | 5 (17)     | 4 (24)     | 8 (17)     | 5 (9)      |         |
| Induction therapy            |       |       |            |            |            | <0.001     |         |
| Basiliximab                 | 73 (42) | 17 (65) | 22 (78)    | 2 (12)     | 28 (80)    | 4 (7)      |         |
| rATG                        | 49 (28) | 8 (31)  | 7 (24)     | 7 (41)     | 15 (52)    | 12 (22)    |         |
| rATG, PE, IVIG              | 52 (30) | 1 (4)   | 0          | 8 (47)     | 4 (8)      | 39 (71)    |         |
| Maintenance IS              |       |       |            |            |            | <0.001     |         |
| Tac/MMF/steroids            | 163 (94) | 25 (96) | 25 (86)    | 15 (88)    | 44 (94)    | 54 (96)    | 0.058   |
| Time of diagnosis, d (range) | 70 (2–357) | 74 (2–204) | 30 (6–357) | 24 (7–351) | 80 (2–301) | 61 (5–323) | 0.976   |
| For–cause biopsy, d (range)  | 120 (69) | 17 (65) | 25 (86)    | 16 (94)    | 26 (55)    | 36 (66)    | 0.009   |
| Treatment of rejection       |       |       |            |            |            | <0.001     |         |
| Methylprednisolone          | 81     | 18 (69) | 8 (28)     | 1 (6)      | 37 (79)    | 17 (31)    |         |
| rATG                        | 27     | 7 (27)  | 15 (52)    | 3 (18)     | 2 (4)      | 0          |         |
| PE, IVIG                    | 58     | 1 (4)   | 6 (21)     | 13 (76)    | 5 (11)     | 33 (60)    |         |
| None                        | 8      | 0       | 0          | 3 (6)      | 5 (9)      |            |         |

*Comparing ABMRV/DSA– and ABMRV/DSA+ rejection phenotypes.

MFI) at transplant had undergone plasma exchange (PE) prior to transplantation and intravenous immunoglobulin (IVIG) as additional treatment (N = 52). The later described multivariable Cox regression model was adjusted based on induction immunosuppression to eliminate confounding variables.

Patients with rejection were treated by steroid pulses [18 (69%) TCMVR; 8 (28%) ABMRV/DSA–; 1 (6%) ABMRV/DSA+;
37 (79%) ABMR/DSA--; 17 (31%) ABMR/DSA+[ or rATG
[7 (27%) TCMRV; 15 (52%) ABMRV/DSA--; 3 (18%)
ABMRV/DSA++; 2 (4%) ABMR/DSA-, none of ABMR/DSA+] 
and/or plasmapheresis/IVIG [1 (4%) TCMRV; 6 (21%)
ABMRV/DSA--; 13 (77%) ABMRV/DSA++; 5 (11%) ABMR/DSA–
; 35 (60%) ABMR/DSA+]. Altogether, eight patients were not 
treated mostly due to concomitant infectious complications.

**Surveillance and Subsequent Biopsies**

Altogether, 124 patients from the whole cohort underwent 
at least one biopsy after the diagnostic examination. All 
patients who experienced intimal arteritis in early biopsies 
were eligible for surveillance biopsy at 3 months after the 
first biopsy. After obtaining written informed consent, 60 out 
of the 72 patients (83%) who experienced intimal arteritis 
underwent the surveillance biopsy. Patients from ABMR/DSA–
and ABMR/DSA+ groups underwent subsequent biopsies either 
at the time of center protocol biopsy at the third month 
or when clinically indicated due to graft function worsening 
or proteinuria.

**Statistical Analyses**

Continuous variables were expressed as median and range. 
Categorical variables were expressed as n and percentage of 
the total. Categorical Banff histologic scores were expressed as 
count per category. The Chi-square, ANOVA, Kruskal–Wallis, 
and Wilcoxon tests were used for hypothesis testing when appropriate. 
p < 0.05 were considered statistically significant. Survival 
analyses were performed with the Kaplan–Meier method using the log-rank test. To identify factors associated 
with death-censored graft failure and the development of TG, 
univariable Cox regression was created. For the multivariable 
model, all variables with p < 0.1 were selected, and only 
variables without missing data were included. Data analyses 
were performed using IBM SPSS 22 (SPSS, Inc. Chicago, IL), R 
Studio 4.0.3. (2020-10-10), and GraphPad Prism5 (Graph Pad, 
San Diego, CA).

**RESULTS**

**Demographics and Clinical Characteristics**

In 174 patients, five different rejection phenotypes were 
identified: 26 TCMRV, 29 ABMRV/DSA–, 17 ABMRV/DSA+, 
47 ABMR/DSA–, and 55 ABMR/DSA+ (Table 1). Diabetes, 
ischemic nephropathy, and glomerulonephritis were the 
most common original diseases. DSA– phenotypes were 
more common after the first transplantation. DSA positive 
phenotypes were more frequent in retransplantation. Peak 
PRA was significantly higher in DSA positive groups. Cohort 
 demographics are given in Table 2.

**Surveillance Biopsies**

Surveillance biopsies at 3 months after vascular rejection 
diagnosis were performed in 21 out of 26 patients (81%) with 
TCMRV, 24 out of 29 (83%) patients with DSA negative ABMRV, 
15 out of 17 (88%) patients with DSA positive ABMRV. At case 
biopsy, DSA negative patients with ABMRV did not differ from 
DSA positive ABMRV patients in any of the histologic scores, 
indicating acute inflammation (g, ptc, i, t, v). The only significant 
difference was the intensity of C4d (p = 0.003). Surveillance
FIGURE 2 | The development of Banff score between diagnostic (dg biopsy) and rebiopsies in a subgroup of patients with consented rebiopsies. (A) TCMRV \( n = 21 \) (B) ABMRV DSA– \( n = 22 \) and (C) ABMRV DSA+ \( n = 15 \). Differences were calculated by Wilcoxon matched-paired signed rank test. *\( p < 0.05 \), **\( p < 0.01 \), and ***\( p < 0.001 \).
biopsies revealed the resolution of rejection in 19 (90%) TCMRV cases, 14 (58%) ABMRV/DSA- cases, and only four (27%) ABMRV/DSA+ cases \( (p = 0.006) \). When comparing case and surveillance biopsies, patients with TCMRV had significantly improved i, t, and v scores, and DSA- patients with ABMRV had significantly improved in g, ptc, i, t, and v scores; however, in DSA+ ABMRV cases, only the v-score had improved (Figure 2, Table 3).

**Development of TG**

Significant differences between ABMR rejection phenotypes were found when we studied the development of the TG. For cause and surveillance, biopsies at the 3-year follow-up were included in the analysis. Estimate of the cumulative proportion of patients without TG (TG-free survival) at 36 months was 100% in TCMRV, 85% in ABMRV/DSA-, 65% in ABMRV/DSA−, 54% in ABMRV/DSA+, and 31% ABMRV/DSA+ (log rank \( p < 0.001 \)). Pairwise comparisons showed a significantly longer time to TG in the TCMRV group than in other groups (log rank \( p < 0.05 \)). Interestingly, DSA– patients with ABMRV patients had a significantly shorter time to TG development than DSA– ABMR patients (mean for survival time without TG was 26 and 32 months, respectively) (log rank \( p = 0.035 \) (Figure 3).

Cox regression models were performed to identify risk factors for the development of TG in patients with histologic ABMR. Risk factors identified in the univariable analysis were included in the multivariable model (retransplantation status, DSA positivity, rATG therapy, rATG + PE/IVIG therapy, intimal arteritis at case biopsy, and C4d positivity). Multivariable model adjusted for the variables mentioned above found intimal arteritis to be associated with TG development (HR 2.1, \( p = 0.01 \)) (Table 4).

**Kidney Graft Survival**

The graft survival was significantly impaired in DSA+ patients with intimal arteritis as a part of ABMR compared with others (Figure 4). Death-censored kidney graft survival at 36 months was 96% in TCMRV, 98% in ABMRV/DSA−, 86% in ABMRV/DSA−, 79% in ABMRV/DSA+, and 64% in the ABMRV/DSA+ group (log rank \( p = 0.001 \)). Interestingly, DSA– patients with intimal arteritis as part of ABMR experienced similar graft survival as DSA+ patients with ABMR (\( p = 0.507 \)).

Cox regression assessing risk factors for graft failure in ABMR revealed PRA > 20% (HR 4.4, \( p = 0.001 \)), DSA positivity (HR 3.9, \( p = 0.007 \)), retransplantation (HR 4.0, \( p = 0.002 \)), induction with ATG and ATG with additional PE, IVIG (HR 4.1, \( p = 0.021 \)), and C4d positivity (HR 2.5, \( p = 0.041 \)) in the univariable analysis (Table 5). None of these variables were found to be significant in the multivariable model.

**DISCUSSION**

Intimal arteritis, a diagnostic feature of vascular rejection, is a frequent histological finding in kidney allografts (5, 8, 9). In this study, we found that intimal arteritis as part of histologic ABMR represents a risk for early development of TG regardless of the presence or absence of donor-specific anti-HLA antibodies. Therefore, a poor outcome of this phenotype is anticipated. On the other hand, we found that intimal arteritis as part of TCMR has a favorable kidney graft outcome when standard antirejection therapy is applied. Similar to our data, molecular assessment of kidney allografts revealed the early occurrence of isolated intimal arteritis of benign origin after transplantation (10–12).

Previously, vascular rejection, i.e., intimal arteritis, was characterized by a high rate of steroid-resistance and poor kidney allograft outcomes (4, 13). Just recently, the intimal arteritis was shown to be associated with DSA with the detrimental impact of this rejection phenotype on graft survival and was accepted as a diagnostic criterion for ABMR (5, 6).

Interestingly, in DSA– patients with intimal arteritis as part of histologic ABMR, the occurrence of TG was higher than in DSA– patients without intimal arteritis despite histologic ABMR. TG is a frequent morphological finding in chronic antibody mediated rejection, and thus, those patients are at the highest risk for premature kidney allograft loss (14).

In our study, the outcome of DSA negative patients with intimal arteritis along with MVI was similar to DSA+ patients with MVI, but without intimal arteritis. One of the possible explanations for this phenomenon is the hypothetical presence of non-HLA antibodies. The association of both MVI and intimal arteritis with anti-angiotensin II type 1 receptor antibodies has been discussed for more than a decade (15, 16). Besides anti-angiotensin II type 1 receptor antibodies, Delville et al. described the association of MVI and intimal arteritis with broader autoimmune reactivity measured in vitro by renal microvascular endothelial cells crossmatch assay (17). Very recently, NK cells were found to trigger MVI when a mismatch between donor HLA I and recipient inhibitory killer cell immunoglobulin-like receptor was present (18). This missing self- hypothesis may explain poor outcomes of DSA negative patients with microvascular inflammation. Whether such mechanisms are involved in intimal arteritis as well remains unclear.

Intimal arteritis as part of DSA– ABMR has not been entirely studied. A higher prevalence of AT1R positivity was found along with intimal arteritis. DSA– patients with AT1R positivity lost their grafts prematurely (19). On the other hand, a good prognosis of DSA negative patients with antibody mediated rejection histology was found (7). Graft survival of DSA negative patients with intimal arteritis was not specifically addressed in either of these studies.

There is a lack of studies dealing with graft outcomes in different phenotypes of vascular rejection, especially DSA– histologic ABMR with intimal arteritis, since the major Banff classification update in 2013 (6). Rabant et al. analyzed the outcome of patients with early isolated v-lesions and found better outcomes than in other phenotypes (10). Shimizu et al. observed similar outcomes in patients with intimal arteritis as part of both TCMR and ABMR; however, the study cohort was limited to 31 patients (20). Wu et al. compared the outcome of patients with intimal arteritis, classified both according to the grade of intimal arteritis and Banff classification and found that the grade plays a more important role than the Banff category (21). Salazar et al. reported nine out of 10 graft failures in patients with v-lesions (11). Patient numbers in all the mentioned studies above are small, which limits their conclusions. It is important to note that...
FIGURE 3 | Kaplan–Meier analysis of TG-free interval according to rejection phenotype.

TABLE 3 | Comparison of Banff scores between diagnostic and surveillance biopsies for patients with intimal arteritis.

|                | TCMRV | ABMRV/DSA− | ABMRV/DSA+ |
|----------------|-------|------------|------------|
|                | Diagnostic biopsy | Rebiopsy | P-value | Diagnostic biopsy | Rebiopsy | P-value | Diagnostic biopsy | Rebiopsy | P-value |
| N              | 26    | 21         |          | 29      | 23       |          | 17      | 15      |       |
| g              | 25/17/0/0 | 18/0/1/0  | 0.655    | 7/7/9/6 | 15/6/1/1 | 0.001    | 6/7/3/1 | 7/1/5/2 | 0.566 |
| ptc            | 24/1/0/0 | 19/0/0/0  | 1.000    | 14/3/10/2 | 20/2/0/0 | 0.015    | 11/1/5/0 | 11/0/4/0 | 0.705 |
| i              | 12/9/3/2 | 14/4/0/0  | 0.005    | 14/3/8/4 | 19/2/1/0 | 0.021    | 10/3/4/0 | 13/2/0/0 | 0.045 |
| t              | 11/4/4/7 | 11/5/1/1  | 0.010    | 6/8/6/9 | 16/2/1/3 | 0.018    | 9/3/1/4 | 10/4/1/0 | 0.075 |
| ti             | 11/9/4/2 | 13/4/1/0  | 0.020    | 3/8/13/5 | 14/3/4/1 | 0.028    | 6/4/3/4 | 5/6/1/3 | 0.928 |
| v              | 0/19/6/1 | 18/0/1/0  | <0.001   | 0/20/9/0 | 20/2/0/0 | <0.001   | 0/14/2/1 | 12/3/0/0 | 0.003 |
| ci             | 7/19/0/0 | 3/15/0/0  | 0.705    | 5/20/3/0 | 5/11/6/0 | 0.405    | 6/11/0/0 | 3/11/1/0 | 0.102 |
| ct             | 4/21/1/0 | 0/19/0/0  | 1.000    | 1/24/3/0 | 3/13/6/0 | 0.480    | 0/17/0/0 | 0/14/1/0 | 0.317 |
| cg             | 25/11/0/0 | 19/0/0/0  | 0.317    | 26/1/2/0 | 16/4/2/0 | 0.180    | 15/2/0/0 | 8/4/2/1 | 0.015 |
| cv             | 3/16/5/2 | 2/12/3/3  | 1.000    | 5/12/9/2 | 1/15/3/2 | 0.439    | 3/6/6/2 | 4/5/5/1 | 0.565 |
| ah             | 1/21/4/0 | 3/10/5/1  | 0.739    | 3/17/8/1 | 3/14/5/0 | 0.527    | 4/6/7/0 | 1/9/5/0 | 0.608 |
| CAd            | 20/5/0/1 | 16/4/0/0  | 0.366    | 20/6/2/1 | 18/3/1/0 | 0.317    | 5/2/2/8 | 4/4/3/4 | 0.336 |
| IF/TAn         | 7/17/1/0 | 3/15/0/0  | 0.527    | 5/20/3/0 | 5/11/6/0 | 0.405    | 6/10/1/0 | 3/11/1/0 | 0.257 |

Differences were calculated by the Wilcoxon matched–paired signed–rank test.
*Suspicious for recurrence of the original disease.
ABO incompatible transplantation, assumption of accommodation.
Bold P-values represent statistic significance below 0.05.

the repeated updates of Banff classifications on ABMR make the interpretation of former studies problematic (22).

Limitations of our study were a short follow-up period which confined the number of study endpoints, and above all, we were not able to demonstrate the significant impact of vascular rejection in the absence of DSA on graft survival. The incomplete number of surveillance biopsies in the control groups was limiting.
TABLE 4 | Cox regression assessing risk factors of development of transplant glomerulopathy (No. of events is 52) in histologic ABMR rejection categories (ABMR/DSA−, ABMR/DSA+, ABMRV/DSA−, ABMRV/DSA+).

| Variable | Univariable analysis | p-value | Variable | Univariable analysis | p-value |
|----------|----------------------|---------|----------|----------------------|---------|
|          | HR (95% CI)          |         |          | HR (95% CI)          |         |
| ABMRV/DSA− | 1.0 (0.5–2.0) | 0.972   | Basilixamb | 0.4 (0.2–0.7) | 0.002  |
| ABMRV/DSA+ | 2.7 (1.4–5.2) | 0.004   | rATG±PE/IVIG | 2.8 (1.4–5.5) | 0.002  |
| ABMR/DSA−  | 0.3 (0.1–0.6) | 0.001   | Diagnostic biopsy |         |         |
| ABMR/DSA+  | 1.6 (1.0–2.8) | 0.076   | g>0      | 1.0 (0.5–2.1) | 0.937  |
| Donor (living) | 0.5 (0.2–1.4) | 0.179   | ptc>0    | 1.4 (0.8–2.4) | 0.256  |
| PRA>20%   | 1.2 (0.7–2.1) | 0.508   | i>0      | 0.8 (0.4–1.5) | 0.445  |
| DSA positivity | 2.7 (1.5–4.8) | 0.001   | t>0      | 1.3 (0.7–2.3) | 0.351  |
| HLA mm>3  | 1.4 (0.8–2.4) | 0.244   | t>1      | 0.9 (0.5–1.6) | 0.642  |
| HD vintage>3y | 0.9 (0.5–1.5) | 0.609   | v>0      | 1.7 (1.0–2.9) | 0.064  |
| CKD diagnosis |         |         | cl>1     | 1.2 (0.4–3.9) | 0.727  |
| Diabetes  | 1.2 (0.6–2.6) | 0.588   | ct>1     | 1.2 (0.4–3.9) | 0.727  |
| Vascular  | 1.1 (0.8–2.2) | 0.692   | cg>0     | NA      | NA     |
| Glomerulonephritis | 0.7 (0.4–1.3) | 0.277   | cv>1     | 1.0 (0.6–1.7) | 0.947  |
| Hereditary | 1.1 (0.6–2.1) | 0.826   | ah>1     | 1.1 (0.6–1.9) | 0.724  |
| Other     | 1.1 (0.5–2.3) | 0.822   | IF/T>A>1 | 1.6 (0.6–4.3) | 0.388  |
| Retransplantation | 1.8 (1.0–3.1) | 0.040   | C4d>1 | 1.7 (1.0–3.0) | 0.068  |

Multivariable analysis

| Variable | HR (95% CI) | p-value |
|----------|-------------|---------|
| Retransplantation | 0.8 (0.4–1.5) | 0.395 |
| DSA positivity | 2.1 (1.0–4.7) | 0.064 |

**Bold P-values represent statistic significance below 0.05.**

![Death-censored graft survival according to rejection phenotype](image_url)

**FIGURE 4** | Death-censored graft survival according to rejection phenotype.

In conclusion, intimal arteritis along with MVI was found to represent a risk for the early development of TG regardless of the presence or absence of donor-specific anti-HLA.
TABLE 5 | Cox regression assessing risk factors of graft failure (No. of events 23) in histologic ABMR rejection categories (ABMR/DSA–, ABMR/DSA+, ABMRV/DSA–, and ABMRV/DSA+).

| Variable          | Univariable analysis | p-value | Variable          | Univariable analysis | p-value |
|-------------------|----------------------|---------|-------------------|----------------------|---------|
|                   | HR (95% CI)          |         |                   | HR (95% CI)          |         |
| ABMRV/DSA–        | 0.9 (0.3–2.7)        | 0.864   | Basiliximab       | 0.2 (0.1–0.8)        | 0.021   |
| ABMRV/DSA+        | 3.3 (1.3–8.6)        | **0.011** | rATG±PE/IVIG      | 4.1 (1.2–14.1)       | **0.021** |
| ABMR/DSA–         | 0.1 (0.0–0.7)        | 0.020   | Diagnostic biopsy |                       |         |
| ABMR/DSA+         | 1.7 (0.8–4.0)        | 0.192   | g>0               | 0.6 (0.2–1.5)        | 0.294   |
| Donor (living)    | 0.3 (0.0–2.2)        | 0.239   | ptc>0             | 1.6 (0.7–3.7)        | 0.295   |
| PRA>20%           | 4.4 (1.8–10.8)       | **0.001** | i>0               | 1.5 (0.6–3.4)        | 0.400   |
| DSA positivity    | 3.9 (1.4–10.6)       | **0.007** | t>0               | 1.3 (0.6–3.0)        | 0.574   |
| HD vintage> 3y    | 1.5 (0.7–3.6)        | 0.334   | t>1               | 1.3 (0.6–3.2)        | 0.527   |
| CKD diagnosis     | 1.1 (0.5–2.5)        | 0.871   | v>0               | 1.9 (0.9–4.6)        | 0.112   |
| Diabetes          | 0.04 (0.0–7.0)       | 0.221   | c>1               | 0.9 (0.1–6.7)        | 0.918   |
| Vascular          | 1.8 (0.7–4.5)        | 0.185   | cpg>0             | 0.04 (0.0–20.0)      | 0.314   |
| Glomerulonephritis| 1.3 (0.5–3.1)        | 0.570   | c<1               | 1.9 (0.8–4.3)        | 0.145   |
| Hereditary        | 0.9 (0.3–2.6)        | 0.792   | ah>1              | 1.5 (0.7–3.6)        | 0.312   |
| Other             | 1.0 (0.3–3.2)        | 0.943   | IF/TA>1           | 1.7 (0.4–7.6)        | 0.441   |
| Transplantation   | 4.0 (1.7–9.6)        | **0.002** | C4d>1             | 2.5 (1.0–6.3)        | **0.041** |

Bold P-values represent statistic significance below 0.05.

antibodies. Therefore, it is likely that this phenotype reflects the presence of harmful endothelial injury of different origin than humoral alloimmunity.

DATA AVAILABILITY STATEMENT

The data analyzed in this study is subject to the following licenses/restrictions: Data are stored as medical records of Institute for Clinical and Experimental Medicine, Prague, Czechia. Requests to access these datasets should be directed to Department of Nephrology, Institute for Clinical and Experimental Medicine.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethical Board of Institute for Clinical and Experimental Medicine approved the study under No.: 15-265191A. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

MN: data gathering and processing and manuscript writing. PH: serum and sample storage and assessment and data processing. MK and LV: assessment of histological slides. KK and AS: HLA typing and anti-HLA antibodies evaluation. OV: manuscript writing and supervising. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by the Ministry of Health of the Czech Republic MZO 00023001 and by the Ministry of Health of the Czech Republic under grants NV19-06-00031 and NU21-06-00021.

REFERENCES

1. Parajuli S, Aziz F, Garg N, Panzer SE, Joachim E, Muth B, et al. Histopathological characteristics and causes of kidney graft failure in the current era of immunosuppression. World J Trans. (2019) 9:123–35. doi: 10.5500/wjt.v9.i6.123
2. Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, et al. The Banff 2019. Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. (2020) 20:2318–31. doi: 10.1111/ajt.15898
3. Madill-Thomsen K, Perkowska-Ptasilska A, Bohmig GA, Eskandary F, Einecke G, Gupta G, et al. Discrepancy analysis comparing molecular and histology diagnoses in kidney transplant biopsies. Am J Transplant. (2020) 20:1341–50. doi: 10.1111/ajt.15752
4. Hsu AC, Arbus GS, Noriega E, Huber J. Renal allograft biopsy: a satisfactory adjunct for predicting renal function after graft rejection. Clin Nephrol. (1976) 5:260–5.
5. Lefaucheur C, Loupy A, Vernerey D, Duong-Van-Huyen JP, Suberbielle C, Angiehieu D, et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet. (2013) 381:313–9. doi: 10.1016/S0140-6736(12)61265-3
6. Haas M, Sis B, Racsen LC, Solez K, Glotz D, Calvin RB, et al. Banff 2013 meeting report: Inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial
lesions. *Am J Transplant.* (2014) 14:272–83. doi: 10.1111/apt.12590
7. Senev A, Coemans M, Lerut E, Van Sandt V, Daniëls L, Kuypers D, et al. Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: clinical presentation and implications for outcome. *Am J Transplant.* (2019) 19:763–80. doi: 10.1111/ajt.15074
8. Novotny M, Hruba P, Vichova P, Maluskova J, Honsova E, Viklicky O, et al. Isolated v-lesion represents a benign phenotype of vascular rejection of the kidney allograft – a retrospective study. *Transplant Int.* (2018) 31:1153–63 doi: 10.1111/tri.13286
9. Teo RZC, Wong G, Russ GR, Lim WH. Cell-mediated and humoral acute vascular rejection and graft loss: a registry study. *Nephrology.* (2016) 21:147–55. doi: 10.1111/nep.12577
10. Rabant M, Boulenger F, Gnenmi V, Pellé G, Glowacki F, Hertig A, et al. Isolated v-lesion in kidney transplant recipients: characteristics, association with DSA, and histological follow-up. *Am J Transplant.* (2018) 18:972–81. doi: 10.1111/ajt.14617
11. Salazar IDR, López MM, Chang J, Halloran PF. Reassessing the significance of intimal arteritis in kidney transplant biopsy specimens. *J Am Soc Nephrol.* (2015) 26:3190–8. doi: 10.1681/ASN.2014111064
12. Wohlfahrtova M, Hruba P, Vichova P, Maluskova J, Honsova E, Viklicky O, et al. Early isolated V-lesion may not truly represent rejection of the kidney allograft. *Clin Sci.* (2018) 132:2269–84. doi: 10.1042/CS20180745
13. Nickelet V, Vamvakas EC, Pascual M, Poletti BJ, Colvin RB. The prognostic significance of specific arterial lesions in acute renal allograft rejection. *J Am Soc Nephrol.* (1998) 9:1301–8. doi: 10.1681/ASN.V971301
14. Loupy A, Aubert O, Orandi BJ, Naesens M, Bouatou Y, Raynaud M, et al. Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. *BMJ.* (2019) 366:i4923. doi: 10.1136/bmj.i4923
15. Dragun D, Bräsen JH, Schönemann C, Fritsche L, Budde K, Neumayer H-H, et al. Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptor. *Transplant Proc.* (2003) 35:2104–5. doi: 10.1016/S0041-1345(03)00680-8
16. Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. *N Engl J Med.* (2005) 352:558–69. doi: 10.1056/NEJMoa053577
17. Delville M, Lamartíhe B, Pagie S, See SB, Rabant M, Burger C, et al. Early acute microvascular kidney transplant rejection in the absence of anti-HLA antibodies is associated with preformed IgG antibodies against diverse glomerular endothelial cell antigens. *J Am Soc Nephrol.* (2019) 30:692–709. doi: 10.1681/ASN.2018080868
18. Koenig A, Chen CC, Marçais A, Barba T, Mathias V, Sicard A, et al. Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants. *Nat Commun.* (2019) 10:5350. doi: 10.1038/s41467-019-13113-5
19. Lefaucheur C, Viglietti D, Bouatou Y, Philippe A, Pievani D, Aubert O, et al. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. *Kidney Int.* (2019) 96:189–201. doi: 10.1016/j.kint.2019.01.030
20. Shimizu T, Ishida H, Hayakawa N, Shibahara R, Tanabe K. Clinical and pathological analyses of cases of acute vascular rejection after kidney transplantation. *Transplant Proc.* (2017) 49:2251–5. doi: 10.1016/transproceed.2017.09.046
21. Wu K, Budde K, Schmidt D, Neumayer H-H, Rudolph B. The relationship of the severity and category of acute rejection with intimal arteritis defined in banff classification to clinical outcomes. *Transplantation.* (2015) 99:e105–14. doi: 10.1097/TP.0000000000000640
22. Lamarche C, Côté J-M, Sénécal L, Cardinal H. Efficacy of acute cellular rejection treatment according to banff score in kidney transplant recipients. *Transplant Direct.* (2016) 2:e115. doi: 10.1097/TXD.0000000000000626

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Novotny, Hruba, Kment, Voska, Kabrtova, Slavec and Viklicky. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.